RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Clinical trials for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GLIOBLASTOMA, IDH-WILDTYPE trials appear
Sign up with your email to follow new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug combo targets recurrent brain cancer
Disease control TerminatedThis early-stage trial tests the safety and best dose of the drug triapine combined with radiation therapy for people whose glioblastoma or astrocytoma has returned. Triapine may slow tumor growth by blocking certain enzymes, while radiation aims to kill cancer cells. The study i…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for aggressive brain cancer: drug combo shows promise in early trial
Disease control TerminatedThis study tests a new drug (selinexor) added to standard chemotherapy (temozolomide) for people with a type of brain cancer called glioblastoma that has returned after initial treatment. The goal is to see if the combination is safe and works better than chemotherapy alone at sh…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC